A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.
EGFR Gene Mutation|Lung Cancer|Lung Cancer Metastatic
DRUG: Dacomitinib|DRUG: Osimertinib
Overall Response Rate, Overall response rate (partial and complete responses) of dacomitinib in participants with EGFR-mutant lung cancers and disease progression on osimertinib, 1 year
Progression-free survival, 1 year|Overall survival, 1 year
The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.